close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Oncorus, Inc.

News headline image
Oncorus Announces Workforce Reduction Plan
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus to Participate in Upcoming Investor Conferences
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
News headline image
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
From Oncorus, Inc.
Via GlobeNewswire
Tickers ONCR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today